Category: Cellectis (CLLS) Announces Clinical Hold of UCART123 Studies After Death

Cellectis (CLLS) Announces Clinical Hold of UCART123 Studies After Death

  1. Cellectis (CLLS) Announces Clinical Hold of UCART123 Studies After Death  StreetInsider.com
  2. France’s Cellectis told to pause cell therapy tests after death  Channel NewsAsia
  3. Cellectis to Participate in Upcoming Investor Conferences  Stockhouse
  4. Full coverage

from Business – Google News https://www.streetinsider.com/Corporate+News/Cellectis+%28CLLS%29+Announces+Clinical+Hold+of+UCART123+Studies+After+Death/13263012.html

Advertisements